We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+25.66%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.77B
AUM Growth
+$373M
Cap. Flow
-$163M
Cap. Flow %
-2.41%
Top 10 Hldgs %
45.13%
Holding
79
New
15
Increased
25
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$108M
2
IMTX icon
Immatics
IMTX
+$99.3M
3
MRUS
Merus
MRUS
+$70.4M
4
DYN icon
Dyne Therapeutics
DYN
+$69.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$63.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$398M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$314M
3
CLDX icon
Celldex Therapeutics
CLDX
+$137M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$98.5M
5
VCEL icon
Vericel Corp
VCEL
+$70.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
$103M 1.52%
5,480,577
+283,558
+5% +$6.54M
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$94M 1.39%
288,684
+223,624
+344% +$54.9M
DYN icon
28
Dyne Therapeutics
DYN
$4.9B
$87.8M 1.3%
+3,091,587
New +$69.9M
ETNB
29
DELISTED
89bio
ETNB
$85.9M 1.27%
7,378,548
+1,799,617
+32% +$19.9M
SYRE icon
30
Spyre Therapeutics
SYRE
$9.25B
$84.7M 1.25%
2,232,760
– –
VCEL icon
31
Vericel Corp
VCEL
$2.31B
$83.6M 1.23%
1,606,397
-1,606,397
-50% -$70.4M
CRGX
32
DELISTED
CARGO Therapeutics
CRGX
$83.4M 1.23%
3,735,619
-1,440,213
-28% -$34.3M
RDNT icon
33
RadNet
RDNT
$5.69B
$82.7M 1.22%
1,700,550
+1,036,948
+156% +$41.8M
TMO icon
34
Thermo Fisher Scientific
TMO
$220B
$64.2M 0.95%
110,500
+60,500
+121% +$33.9M
TXG icon
35
10x Genomics
TXG
$6.61B
$58.4M 0.86%
1,554,856
+4,905
+0.3% +$216K
STOK icon
36
Stoke Therapeutics
STOK
$2.11B
$57M 0.84%
4,224,838
+93,793
+2% +$568K
FULC icon
37
Fulcrum Therapeutics
FULC
$297M
$55.2M 0.81%
5,845,956
+376,000
+7% +$3.36M
TSHA icon
38
Taysha Gene Therapies
TSHA
$1.89B
$53.4M 0.79%
18,593,185
+1,700,000
+10% +$3.54M
INSM icon
39
Insmed
INSM
$28.6B
$50.6M 0.75%
1,865,108
– –
URGN icon
40
UroGen Pharma
URGN
$2.29B
$48.9M 0.72%
3,257,347
+1,530,539
+89% +$25M
KYTX icon
41
Kyverna Therapeutics
KYTX
$484M
$46M 0.68%
+1,852,711
New +$51.7M
ISRG icon
42
Intuitive Surgical
ISRG
$134B
$39.5M 0.58%
+99,000
New +$37.4M
NGNE icon
43
Neurogene
NGNE
$712M
$39.1M 0.58%
+769,122
New +$25.7M
JANX icon
44
Janux Therapeutics
JANX
$967M
$37.6M 0.56%
+1,000,000
New +$21.8M
GHRS icon
45
GH Research
GHRS
$2.08B
$35.5M 0.52%
3,327,129
– –
OBIO icon
46
Orchestra BioMed
OBIO
$254M
$29.6M 0.44%
5,620,640
– –
DNTH icon
47
Dianthus Therapeutics
DNTH
$6.09B
$20M 0.3%
+666,667
New +$14.5M
EPIX
48
DELISTED
ESSA Pharma
EPIX
$19.5M 0.29%
2,298,662
– –
LENZ
49
LENZ Therapeutics
LENZ
$168M
$19.3M 0.28%
+863,389
New +$17.9M
CGON icon
50
CG Oncology
CGON
$6.66B
$18.2M 0.27%
+413,670
New +$16.9M
1
2
3 4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q1 2024 Portfolio in Review

As of Q1 2024, RTW Investments held 79 positions worth $6.77B, up 5.8% from $6.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments's Q1 2024 filing shows 15 new, 25 increased, 7 reduced and 10 closed positions. Its largest new stake was Stryker: 321,000 shares worth $115M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $398M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q1 2024 buy was Stryker: 321,000 shares worth $115M.
  • RTW Investments added most to Immatics in Q1 2024, an estimated $99.3M increase.
  • RTW Investments's biggest Q1 2024 reduction was Madrigal Pharmaceuticals, cutting an estimated $98.5M.
  • RTW Investments fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $398M.
  • RTW Investments's ten largest holdings make up 45% of its $6.77B portfolio in Q1 2024.
  • RTW Investments opened 15 new positions and closed 10 in Q1 2024.
  • RTW Investments's portfolio value rose 5.8% quarter-over-quarter to $6.77B.

Based on RTW Investments's 13F filing for Q1 2024, filed 15 May 2024.